person · Reporting owner
Schimmelpennink Evert B.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director | June 26, 2026 | June 26, 2026 |
| LENZ Therapeutics, Inc.LENZ · Entity 6475 | Director · President, CEO and Secretary | March 27, 2026 | March 30, 2026 |
| iBio, Inc.IBIO · Entity 6906 | Director | November 20, 2025 | November 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date June 26, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2036-06-25 | Direct | 19,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 19,000 · Balance 19,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
LENZ Therapeutics, Inc.
Report date March 27, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,289 |
Reported balance
After 2026-03-27 transaction · row 1
1 source rowRow 1 · 2026-03-27 · Purchase · Acquired 28,089 · Balance 77,289 F1: Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
iBio, Inc.
Report date November 20, 2025 · Filed November 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-11-19 | Direct | 13,500 |
Reported balance
After 2025-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-20 · Grant · Acquired 13,500 · Balance 13,500 F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pfenex Inc.
Report date October 01, 2020 · Filed October 05, 2020
Section 16 reporting ended · disclosed 2020-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Other · Disposed 16,658 · Balance 0 F1: Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated August 10, 2020 (the "Merger Agreement"), by and among Ligand Pharmaceutical Incorporated, a Delaware corporation, Pelican Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent, and the Issuer, each issued and outstanding share of Issuer common stock (other than (A) Cancelled Shares, (B) Accepted Company Shares, and (C) Dissenting Company Shares (each as defined in the Merger Agreement)) was automatically converted into the right to receive (i) $12.00 per share, net to the holder thereof, subject to reduction for any applicable withholding Taxes (as defined in the Merger Agreement) payable in respect thereof, in cash (the "Cash Portion"), and (ii) a non-transferrable contractual contingent value right per share (a "CVR"), pursuant to the Contingent Value Rights Agreement, F2: (continued from footnote 1) dated as of September 30, 2020 (as it may be amended from time to time, the "CVR Agreement"), to receive a contingent payment of $2.00 in cash upon the achievement of a specified milestone as set forth in the CVR Agreement (the "CVR Portion"), effective immediately prior to the Effective Time (as defined in the Merger Agreement). |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-10-01 · Other · Disposed 10,000 · Balance 0 F1: Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated August 10, 2020 (the "Merger Agreement"), by and among Ligand Pharmaceutical Incorporated, a Delaware corporation, Pelican Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent, and the Issuer, each issued and outstanding share of Issuer common stock (other than (A) Cancelled Shares, (B) Accepted Company Shares, and (C) Dissenting Company Shares (each as defined in the Merger Agreement)) was automatically converted into the right to receive (i) $12.00 per share, net to the holder thereof, subject to reduction for any applicable withholding Taxes (as defined in the Merger Agreement) payable in respect thereof, in cash (the "Cash Portion"), and (ii) a non-transferrable contractual contingent value right per share (a "CVR"), pursuant to the Contingent Value Rights Agreement, F2: (continued from footnote 1) dated as of September 30, 2020 (as it may be amended from time to time, the "CVR Agreement"), to receive a contingent payment of $2.00 in cash upon the achievement of a specified milestone as set forth in the CVR Agreement (the "CVR Portion"), effective immediately prior to the Effective Time (as defined in the Merger Agreement). F3: Shares held by the Schimmelpennink-Van Alphen Trust, dated 7/31/2019, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.52 · Expires 2027-09-01 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Other · Disposed 36,290 · Balance 0 F5: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F4: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 · Expires 2028-02-01 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Other · Disposed 195,062 · Balance 0 F5: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F6: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2018. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Other · Disposed 300,000 · Balance 0 F5: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F7: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.89 · Expires 2030-02-03 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-01 · Other · Disposed 225,000 · Balance 0 F5: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F8: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.52 · Expires 2027-09-01 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-01 · Other · Disposed 313,710 · Balance 0 F5: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F9: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2016 Inducement Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated August 10, 2020 (the "Merger Agreement"), by and among Ligand Pharmaceutical Incorporated, a Delaware corporation, Pelican Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent, and the Issuer, each issued and outstanding share of Issuer common stock (other than (A) Cancelled Shares, (B) Accepted Company Shares, and (C) Dissenting Company Shares (each as defined in the Merger Agreement)) was automatically converted into the right to receive (i) $12.00 per share, net to the holder thereof, subject to reduction for any applicable withholding Taxes (as defined in the Merger Agreement) payable in respect thereof, in cash (the "Cash Portion"), and (ii) a non-transferrable contractual contingent value right per share (a "CVR"), pursuant to the Contingent Value Rights Agreement,
F2: (continued from footnote 1) dated as of September 30, 2020 (as it may be amended from time to time, the "CVR Agreement"), to receive a contingent payment of $2.00 in cash upon the achievement of a specified milestone as set forth in the CVR Agreement (the "CVR Portion"), effective immediately prior to the Effective Time (as defined in the Merger Agreement).
F3: Shares held by the Schimmelpennink-Van Alphen Trust, dated 7/31/2019, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees.
F4: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017.
F5: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings
F6: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2018.
F7: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2019.
F8: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2020.
F9: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2016 Inducement Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 26, 2026 21:44 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001628280-26-045839 · wk-form4_1782510265.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Class A Common Stock · 19,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 12:46 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | PurchaseCommon Stock | 28,089 | $8.95 | $251,410.59 |
DisclosureSEC source: 0001713795-26-000004 · wk-form4_1774874815.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,289 F1 · price: Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:21 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 358,100 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001713795-26-000002 · wk-form4_1767734492.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,100 Underlying: Common Stock · 358,100 shares Expires 2036-01-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 2, 2026. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:10 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-25-115414 · tm2532045-6_4seq1.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-11-19 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| June 26, 2025 Filed Jun 26, 2025 21:47 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 14,750 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001437749-25-021372 · rdgdoc.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Underlying: Class A Common Stock · 14,750 shares Expires 2035-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:10 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | Exercise / conversionStock Option (right to buy) · Derivative | 4,200 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001815776-25-000011 · wk-form4_1741389036.xml · derivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,906 Underlying: Common Stock · 4,200 shares Expires 2031-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 8, 2021. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:10 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | Exercise / conversionCommon Stock | 4,200 | $1.04 | $4,368.00 |
DisclosureSEC source: 0001815776-25-000011 · wk-form4_1741389036.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 22:20 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 279,100 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0001815776-25-000003 · wk-form4_1736806836.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,100 Underlying: Common Stock · 279,100 shares Expires 2035-01-08 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 9, 2025. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:33 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-122593 · tm2429436-5_4seq1.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2034-11-20 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 00:16 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001815776-24-000051 · wk-form4_1721780188.xml · derivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,106 Underlying: Common Stock · 45,000 shares Expires 2031-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 8, 2021. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 00:16 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | Exercise / conversionCommon Stock | 45,000 | $1.04 | $46,800.00 |
DisclosureSEC source: 0001815776-24-000051 · wk-form4_1721780188.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:53 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018618 · rdgdoc.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Class A Common Stock · 29,500 shares Expires 2034-05-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on April 5, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:32 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000020 · wk-form4_1711413134.xml · derivative · entry 4 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2034-03-20 F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:32 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 315,864 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001815776-24-000020 · wk-form4_1711413134.xml · derivative · entry 3 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,864 Underlying: Common Stock · 315,864 shares Expires 2033-06-19 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 6, 2023. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:32 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 82,723 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000020 · wk-form4_1711413134.xml · derivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,723 Underlying: Common Stock · 82,723 shares Expires 2032-11-23 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 8, 2021. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:32 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 387,106 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001815776-24-000020 · wk-form4_1711413134.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,106 Underlying: Common Stock · 387,106 shares Expires 2031-03-07 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 8, 2021. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:09 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001104659-21-149236 · tm2135158-2_4seq1.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2031-12-08 F1 · security: These options vest pro rata on a monthly basis over 12 months. F1 · shares: These options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:19 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-21-078869 · tm2119289d1_4.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-06 F1 · shares: These options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:30 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherStock Option (right to buy) · Derivative | 313,710 | Not disclosed Strike: $3.52 | Not disclosed |
DisclosureSEC source: 0000899243-20-027411 · doc4.xml · derivative · entry 7 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 313,710 shares Expires 2027-09-01 F5 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F9 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2016 Inducement Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:30 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherStock Option (right to buy) · Derivative | 225,000 | Not disclosed Strike: $10.89 | Not disclosed |
DisclosureSEC source: 0000899243-20-027411 · doc4.xml · derivative · entry 6 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2030-02-03 F5 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F8 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:30 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherStock Option (right to buy) · Derivative | 300,000 | Not disclosed Strike: $3.90 | Not disclosed |
DisclosureSEC source: 0000899243-20-027411 · doc4.xml · derivative · entry 5 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2029-02-01 F5 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F7 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2019. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:30 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherStock Option (right to buy) · Derivative | 195,062 | Not disclosed Strike: $3.38 | Not disclosed |
DisclosureSEC source: 0000899243-20-027411 · doc4.xml · derivative · entry 4 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,062 shares Expires 2028-02-01 F5 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F6 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2018. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:30 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherStock Option (right to buy) · Derivative | 36,290 | Not disclosed Strike: $3.52 | Not disclosed |
DisclosureSEC source: 0000899243-20-027411 · doc4.xml · derivative · entry 3 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,290 shares Expires 2027-09-01 F5 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings F4 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:30 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027411 · doc4.xml · nonDerivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated August 10, 2020 (the "Merger Agreement"), by and among Ligand Pharmaceutical Incorporated, a Delaware corporation, Pelican Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent, and the Issuer, each issued and outstanding share of Issuer common stock (other than (A) Cancelled Shares, (B) Accepted Company Shares, and (C) Dissenting Company Shares (each as defined in the Merger Agreement)) was automatically converted into the right to receive (i) $12.00 per share, net to the holder thereof, subject to reduction for any applicable withholding Taxes (as defined in the Merger Agreement) payable in respect thereof, in cash (the "Cash Portion"), and (ii) a non-transferrable contractual contingent value right per share (a "CVR"), pursuant to the Contingent Value Rights Agreement, F2 · price: (continued from footnote 1) dated as of September 30, 2020 (as it may be amended from time to time, the "CVR Agreement"), to receive a contingent payment of $2.00 in cash upon the achievement of a specified milestone as set forth in the CVR Agreement (the "CVR Portion"), effective immediately prior to the Effective Time (as defined in the Merger Agreement). F3 · ownership.nature: Shares held by the Schimmelpennink-Van Alphen Trust, dated 7/31/2019, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:30 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherCommon Stock | 16,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027411 · doc4.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated August 10, 2020 (the "Merger Agreement"), by and among Ligand Pharmaceutical Incorporated, a Delaware corporation, Pelican Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent, and the Issuer, each issued and outstanding share of Issuer common stock (other than (A) Cancelled Shares, (B) Accepted Company Shares, and (C) Dissenting Company Shares (each as defined in the Merger Agreement)) was automatically converted into the right to receive (i) $12.00 per share, net to the holder thereof, subject to reduction for any applicable withholding Taxes (as defined in the Merger Agreement) payable in respect thereof, in cash (the "Cash Portion"), and (ii) a non-transferrable contractual contingent value right per share (a "CVR"), pursuant to the Contingent Value Rights Agreement, F2 · price: (continued from footnote 1) dated as of September 30, 2020 (as it may be amended from time to time, the "CVR Agreement"), to receive a contingent payment of $2.00 in cash upon the achievement of a specified milestone as set forth in the CVR Agreement (the "CVR Portion"), effective immediately prior to the Effective Time (as defined in the Merger Agreement). Read SEC document |
| February 03, 2020 Filed Feb 3, 2020 20:10 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0000899243-20-002634 · doc4.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2020. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 17:40 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0000899243-19-002485 · doc4.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the Option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2019. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 16:25 UTC | Pfenex Inc. PFNX · Entity 146052 | PurchaseCommon Stock | 500 | $5.01 | $2,505.00 |
DisclosureSEC source: 0000899243-18-024433 · doc4.xml · nonDerivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,658 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 16:25 UTC | Pfenex Inc. PFNX · Entity 146052 | PurchaseCommon Stock | 9,500 | $5.04 | $47,880.00 |
DisclosureSEC source: 0000899243-18-024433 · doc4.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,158 Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:07 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 195,062 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000899243-18-002751 · doc4.xml · derivative · entry 3 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,062 Underlying: Common Stock · 195,062 shares Expires 2028-02-01 F2 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2018. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:07 UTC | Pfenex Inc. PFNX · Entity 146052 | Tax withholdingCommon Stock | 11,236 | $3.38 | $37,977.68 |
DisclosureSEC source: 0000899243-18-002751 · doc4.xml · nonDerivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,658 Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:07 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantCommon Stock | 27,894 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002751 · doc4.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,894 F1 · security: Grant of restricted stock units pursuant to the Issuer's 2014 Equity Incentive Plan. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on the February 1, 2018. F1 · shares: Grant of restricted stock units pursuant to the Issuer's 2014 Equity Incentive Plan. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on the February 1, 2018. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 17:06 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 36,290 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0000899243-17-021367 · doc4.xml · derivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,290 Underlying: Common Stock · 36,290 shares Expires 2027-09-01 F2 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 17:06 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 313,710 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0000899243-17-021367 · doc4.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,710 Underlying: Common Stock · 313,710 shares Expires 2027-09-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2016 Inducement Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean August 3, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.